Molbio Diagnostics Targets ₹940 Crore in IPO for Growth and Stake Sale

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise ₹940 crore. This financial move is split into a fresh issue of ₹200 crore intended for capital expenditures and an offer for sale generating ₹740 crore to reduce the promoter group's stake from 46.6% to 43%.

Expanding Global Reach and Revenue Sources

Established in 2000, Molbio Diagnostics has built a robust presence with six manufacturing facilities in India, serving clients across more than 90 countries. The company is particularly known for its innovative 'Truenat' platform, a portable diagnostic system that delivers rapid and accurate results for over 30 diseases, including tuberculosis. This platform has been instrumental in addressing healthcare needs in resource-limited settings.

Molbio's clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations, with a notable concentration of revenue from its top clients. Government and international aid agencies contribute significantly to its income, accounting for over 80% of the company's revenue.

Financial Performance and Market Position

The financial performance of Molbio Diagnostics has been robust, with a 31.5% annual increase in revenue to ₹1,445.7 crore and a 40.2% growth in net profit reaching ₹164.1 crore between FY24 and FY26. The company’s EBITDA rose 33.2% to ₹328.2 crore, reflecting an improved EBITDA margin of 22.6% in FY26, up from 22% in FY24.

In FY26 alone, the company saw a 41.7% increase in revenue, with EBITDA growing by 27.9% and net profit by 18.4%. These figures underscore Molbio's strong market position and its potential to deliver sustained growth.

Investment Considerations and Market Comparisons

For investors with a high-risk appetite, Molbio Diagnostics' IPO presents an opportunity to invest in a company with significant growth potential, driven by its leading diagnostic solutions and expanding international footprint. The IPO demands a price-earnings (P/E) multiple of up to 57, which is competitive when compared to other healthcare diagnostics and medical device companies in India, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81.

While Molbio lacks directly comparable listed peers in India, its strategic focus on innovation and expansion positions it as an attractive option for investors seeking exposure to the burgeoning diagnostics market.